Researchers in Japan have launched clinical trials of an experimental drug designed to stimulate the growth of new teeth in humans. The therapy works by blocking a protein called USAG-1, which normally inhibits tooth development.
Preclinical studies showed that neutralizing this protein with specific antibodies was able to induce the growth of new teeth in animal models affected by tooth agenesis. These findings led researchers to develop a drug intended to reactivate tooth formation in patients with congenital absence of teeth.
Future dentistry
The clinical trial is led by Katsu Takahashi at the Medical Research Institute Kitano Hospital, in Osaka, Japan. The first phase of the study aims to evaluate the safety of the treatment in patients with congenital tooth agenesis, a genetic condition in which some permanent teeth fail to develop.
If the therapy proves to be safe and effective, researchers believe it could open the door to regenerative treatments that allow patients to grow new natural teeth, potentially providing a biological alternative to dental implants or prosthetic restorations.
Although the treatment is still in the early stages of clinical evaluation, the research represents a significant step forward in the field of regenerative dentistry.
Scientific Source:
K. Takahashi et al. — Development of a new antibody drug to treat congenital tooth agenesis
PubMed
https://pubmed.ncbi.nlm.nih.gov/39389160/